# Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

> **NCT01701401** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 870 (actual)

## Conditions studied

- Chronic Hepatitis C Virus

## Interventions

- **DRUG:** LDV/SOF
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT01701401
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-03
- **Final completion:** 2014-04
- **Target enrollment:** 870 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01701401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01701401, "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01701401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*